Induction of nuclear NF-kappa B DNA binding activity after exposure of lymphoid cells to soluble tax1 protein.

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Induction of nuclear NF-kappa B DNA binding activity after exposure of lymphoid cells to soluble tax1 protein.

New Biol. 1990 Nov;2(11):1034-43. Unique Identifier : AIDSLINE MED/91329293
Lindholm PF; Marriott SJ; Gitlin SD; Bohan CA; Brady JN; Laboratory of Molecular Virology, National Cancer Institute,; National Institutes of Health, Bethesda, MD 20892.

Abstract: We demonstrate that purified HTLV-I Tax1 protein can be taken up by 70Z/3 lymphoid cells and localized in both the nuclear and cytoplasmic compartments. Introduction of the Tax1 protein into the growth medium of 70Z/3 cells resulted in the rapid and transient induction of NF-kappa B binding activity in the nuclear fraction. Tax1 activation of NF-kappa B was not sensitive to either staurosporin or prolonged stimulation with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate, suggesting that Tax1-dependent NF-kappa B activation did not require the protein kinase C pathway. Purified Tax1 did not directly increase NF-kappa B binding activity in 70Z/3 cytoplasmic extracts, suggesting that NF-kappa B induction may require cellular factors. Western blot and competitive radioimmunoassays demonstrated that Tax1 protein was present in the tissue culture media of HTLV-I-transformed cell lines. These results show that extracellular Tax1 may regulate cellular gene expression in noninfected cells.

Keywords: Alkaloids/PHARMACOLOGY Animal Cell Transformation, Viral DNA/METABOLISM Gene Expression Regulation, Viral/*DRUG EFFECTS Gene Products, tax/*PHARMACOLOGY/PHARMACOKINETICS Hematopoietic Stem Cells/DRUG EFFECTS/METABOLISM Human HTLV-I/GENETICS/*PHYSIOLOGY Lipopolysaccharides/PHARMACOLOGY Mice NF-kappa B/*BIOSYNTHESIS/GENETICS Protein Binding/DRUG EFFECTS Recombinant Proteins/PHARMACOLOGY Tetradecanoylphorbol Acetate/PHARMACOLOGY Tumor Cells, Cultured/DRUG EFFECTS/METABOLISM JOURNAL ARTICLE

911130
M91B0795

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .